Skip to search formSkip to main contentSkip to account menu

Iluvien

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial… 
2017
2017
IntroductionIt is hypothesized that using fluocinolone acetonide (FAc) implants such as Iluvien for the treatment of diabetic… 
2017
2017
PurposeTo report the 12-months visual and anatomical outcomes of chronic diabetic macular oedema (DMO) treated with ILUVIEN in a… 
2016
2016
Importance: A case showing sustained structural and functional responses 2 years after a single treatment with ILUVIEN (0.2 µg… 
2016
2016
IntroductionWe describe a proactive method using electronic patient records (EPR) to identify pseudophakic patients with diabetic… 
2015
2015
  • F. Kane, K. Green
  • Journal of ocular pharmacology and therapeutics…
  • 2015
  • Corpus ID: 37158770
PURPOSE The purpose of this study was to evaluate the systemic and ocular pharmacokinetics (PK) of fluocinolone acetonide (FAc… 
Review
2015
Review
2013
Review
2013
This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious uveitis… 
Review
2008
Review
2008
Iluvien™ (fluocinolone acetonide intravitreal insert, Alimera Sciences, Inc.), a novel injectable intravitreal insert, is being… 
Review
2008
Review
2008
Iluvien (fluocinolone acetonide intravitreal insert, Alimera Sciences, Inc.), a novel injectable intravitreal insert, is being…